Sign in or create an account to add this stock to your watchlist.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000
Debt
Debt-to-Equity RatioN/A
Current Ratio5.04
Quick Ratio3.90
Price-To-Earnings
Trailing P/E Ratio15.13
Forward P/E Ratio17.56
P/E Growth1.17
Sales & Book Value
Annual Sales$534.46 million
Price / Sales2.96
Cash Flow$4.2284 per share
Price / Cash11.34
Book Value$16.62 per share
Price / Book2.89
Profitability
EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins18.69%
Return on Equity21.00%
Return on Assets15.20%
Miscellaneous
Employees1,228
Outstanding Shares32,960,000
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.22. The biotechnology company earned $141.10 million during the quarter, compared to analysts' expectations of $104.44 million. Cambrex had a return on equity of 21.00% and a net margin of 18.69%. The business's revenue was up 34.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.68 EPS. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What guidance has Cambrex issued on next quarter's earnings?
Cambrex issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided EPS guidance of $2.80 to $3.03 for the period, compared to the Thomson Reuters consensus estimate of $2.90.
What price target have analysts set for CBM?
3 Wall Street analysts have issued twelve-month price targets for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $60.00 in the next year. View Analyst Ratings for Cambrex.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC) and Array Biopharma (ARRY).
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
- Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)
- Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
- Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
- Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)
Has Cambrex been receiving favorable news coverage?
News coverage about CBM stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cambrex earned a daily sentiment score of 0.06 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Cambrex's major shareholders?
Cambrex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.90%), Dimensional Fund Advisors LP (4.27%), Boston Partners (2.06%), Northern Trust Corp (1.76%), Fiera Capital Corp (1.32%) and Neumeier Poma Investment Counsel LLC (1.19%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.
Which institutional investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Penn Capital Management Co. Inc., RMB Capital Management LLC, New York State Common Retirement Fund, Boston Partners, Nuveen Asset Management LLC, Comerica Bank and JW Asset Management LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.
Which institutional investors are buying Cambrex stock?
CBM stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Heartland Advisors Inc., Sei Investments Co., GW&K Investment Management LLC, BlackRock Inc., Carillon Tower Advisers Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $47.95.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.58 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cambrex (NYSE:CBM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Cambrex in the last 12 months. Their average twelve-month price target is $60.00, suggesting that the stock has a possible upside of 25.13%. The high price target for CBM is $60.00 and the low price target for CBM is $60.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $60.00 | $60.00 | $60.00 | $62.3333 |
| Price Target Upside: | 25.13% upside | 9.19% upside | 9.19% upside | 37.91% upside |
Cambrex (NYSE:CBM) Consensus Price Target History
Cambrex (NYSE:CBM) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Cambrex (NYSE:CBM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.42%
Cambrex (NYSE CBM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/8/2018 | Gregory Sargen | EVP | Sell | 67,500 | $49.48 | $3,339,900.00 | |  |
| 5/8/2018 | Shawn Cavanagh | COO | Sell | 40,000 | $49.69 | $1,987,600.00 | | |
| 10/2/2017 | Steven M Klosk | CEO | Sell | 4,000 | $54.96 | $219,840.00 | 87,328 | |
| 9/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $51.53 | $618,360.00 | 95,328 | |
| 8/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $61.39 | $736,680.00 | 95,328 | |
| 7/3/2017 | Steven M Klosk | CEO | Sell | 12,000 | $59.66 | $715,920.00 | 95,328 | |
| 6/12/2017 | Samantha Hanley | VP | Sell | 14,000 | $57.56 | $805,840.00 | 1,500 | |
| 6/6/2017 | Leon J Hendrix Jr | Director | Sell | 20,656 | $55.95 | $1,155,703.20 | 74,662 | |
| 6/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $54.19 | $650,280.00 | 95,328 | |
| 5/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $58.20 | $698,400.00 | 95,328 | |
| 4/3/2017 | Steven M Klosk | CEO | Sell | 12,000 | $54.58 | $654,960.00 | 95,328 | |
| 3/1/2017 | Steven M Klosk | CEO | Sell | 12,000 | $56.70 | $680,400.00 | 95,328 | |
| 2/27/2017 | Shawn Cavanagh | COO | Sell | 19,620 | $55.95 | $1,097,739.00 | 17,658 | |
| 2/16/2017 | Steven M Klosk | CEO | Sell | 23,822 | $52.50 | $1,250,655.00 | 94,241 | |
| 2/13/2017 | Steven M Klosk | CEO | Sell | 63,178 | $52.55 | $3,320,003.90 | 109,062 | |
| 2/7/2017 | Gregory Sargen | EVP | Sell | 30,000 | $54.88 | $1,646,400.00 | 50,000 | |
| 2/7/2017 | Shawn Cavanagh | COO | Sell | 20,380 | $55.12 | $1,123,345.60 | 57,658 | |
| 12/14/2016 | Shawn Cavanagh | COO | Sell | 30,000 | $53.58 | $1,607,400.00 | 27,658 | |
| 11/11/2016 | Gregory Sargen | Insider | Sell | 22,500 | $52.02 | $1,170,450.00 | 27,500 | |
| 7/11/2016 | William B Korb | Director | Sell | 3,420 | $55.00 | $188,100.00 | 23,982 | |
| 6/8/2016 | William B Korb | Director | Sell | 4,142 | $52.47 | $217,330.74 | 24,704 | |
| 6/1/2016 | William B Korb | Director | Sell | 8,000 | $51.06 | $408,480.00 | 25,304 | |
| 5/9/2016 | Steven M Klosk | CEO | Sell | 14,005 | $49.00 | $686,245.00 | 147,333 | |
| 5/5/2016 | Steven M Klosk | CEO | Sell | 16,430 | $49.13 | $807,205.90 | 136,828 | |
| 5/3/2016 | William B Korb | Director | Sell | 8,000 | $49.09 | $392,720.00 | 32,562 | |
| 3/16/2016 | Steven M Klosk | CEO | Sell | 19,565 | $41.00 | $802,165.00 | 152,893 | |
| 3/15/2016 | Louis J Grabowsky | Director | Buy | 750 | $40.10 | $30,075.00 | 928 | |
| 3/10/2016 | William B Korb | Director | Sell | 8,000 | $41.38 | $331,040.00 | 32,562 | |
| 2/11/2016 | Gregory Sargen | CFO | Sell | 13,622 | $36.16 | $492,571.52 | 46,697 | |
| 2/11/2016 | Shawn Cavanagh | COO | Sell | 18,342 | $36.13 | $662,696.46 | 17,658 | |
| 2/11/2016 | Steven M. Klosk | CEO | Sell | 39,542 | $36.20 | $1,431,420.40 | 133,328 | |
| 12/15/2015 | Leon J. Hendrix, Jr. | Director | Sell | 7,000 | $51.34 | $359,380.00 | 71,211 | |
| 12/11/2015 | Peter G. Tombros | Director | Sell | 31,236 | $51.37 | $1,604,593.32 | 21,520 | |
| 11/30/2015 | Ilan Kaufthal | Director | Sell | 52,315 | $54.32 | $2,841,750.80 | 60,000 | |
| 11/13/2015 | Gregory Sargen | CFO | Sell | 28,750 | $49.14 | $1,412,775.00 | 33,319 | |
| 11/6/2015 | Samantha Hanley | VP | Sell | 15,000 | $52.03 | $780,450.00 | | |
| 8/27/2015 | William B. Korb | Director | Sell | 3,600 | $48.00 | $172,800.00 | 46,562 | |
| 5/21/2015 | Ilan Kaufthal | Director | Sell | 50,000 | $41.31 | $2,065,500.00 | | |
| 5/11/2015 | Gregory Sargen | CFO | Sell | 25,000 | $38.44 | $961,000.00 | | |
| 2/12/2015 | Aldo Magnini | Director | Sell | 7,500 | $32.75 | $245,625.00 | | |
| 2/12/2015 | Gregory Sargen | CFO | Sell | 25,000 | $32.64 | $816,000.00 | | |
| 2/10/2015 | Steven M Klosk | CEO | Sell | 45,000 | $30.32 | $1,364,400.00 | | |
| 9/11/2014 | Shawn Cavanagh | COO | Sell | 56,251 | $22.56 | $1,269,022.56 | | |
| 9/3/2014 | Steven M Klosk | CEO | Sell | 126,257 | $22.01 | $2,778,916.57 | | |
| 9/2/2014 | William M Haskel | SVP | Sell | 9,400 | $21.94 | $206,236.00 | | |
| 8/19/2014 | Steven M Klosk | CEO | Sell | 4,702 | $22.00 | $103,444.00 | | |
| 8/7/2014 | Steven M Klosk | CEO | Sell | 1,200 | $22.52 | $27,024.00 | | |
| 8/7/2014 | William M Haskel | SVP | Sell | 28,100 | $22.50 | $632,250.00 | | |
| 8/5/2014 | Gregory Sargen | CFO | Sell | 50,000 | $22.34 | $1,117,000.00 | | |
| 2/28/2014 | Leon Hendrix, Jr. | Director | Sell | 23,000 | $20.09 | $462,070.00 | 92,993 | |
| 2/20/2014 | Aldo Magnini | Director | Sell | 6,000 | $22.10 | $132,600.00 | | |
| 12/5/2013 | Paolo Russolo | Insider | Sell | 35,000 | $18.40 | $644,000.00 | 67,085 | |
| 11/11/2013 | Gregory Sargen | CFO | Sell | 20,000 | $18.92 | $378,400.00 | 33,319 | |
| 11/11/2013 | John Miller | Director | Sell | 2,000 | $19.21 | $38,420.00 | 35,306 | |
| 5/24/2013 | Paolo Russolo | Insider | Sell | 32,903 | $12.53 | $412,274.59 | | |
| 5/16/2013 | Leon J Hendrix Jr | Director | Sell | 1,120 | $13.40 | $15,008.00 | | |
(Data available from 1/1/2013 forward)
Cambrex (NYSE CBM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cambrex (CBM) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 16 at 8:19 PM |
 | Cambrex Completes Pilot Plant Expansion at its High Point, NC Facility
finance.yahoo.com - May 15 at 9:26 AM |
| Cambrex (CBM) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 6:51 PM |
| Shawn Cavanagh Sells 40,000 Shares of Cambrex Co. (CBM) Stock
www.americanbankingnews.com - May 9 at 7:16 PM |
| Cambrex Co. (CBM) EVP Gregory Sargen Sells 67,500 Shares
www.americanbankingnews.com - May 9 at 7:15 PM |
 | Cambrex's (CBM) CEO Steven Klosk on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 9:14 AM |
| Cambrex Co. (CBM) Expected to Post Quarterly Sales of $161.55 Million
www.americanbankingnews.com - May 5 at 3:02 AM |
| Edited Transcript of CBM earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:56 AM |
| Cambrex (CBM) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 3 at 11:47 PM |
| Cambrex (CBM) Releases Earnings Results, Beats Estimates By $0.22 EPS
www.americanbankingnews.com - May 3 at 9:38 PM |
| $0.52 Earnings Per Share Expected for Cambrex Co. (CBM) This Quarter
www.americanbankingnews.com - May 3 at 8:33 PM |
| Cambrex: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 4:48 PM |
| Cambrex (CBM) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 3 at 10:29 AM |
 | Form 10-Q CAMBREX CORP For: Mar 31
www.streetinsider.com - May 3 at 8:56 AM |
| Cambrex Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 8:56 AM |
| Cambrex Co. (CBM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 3 at 1:54 AM |
| Form 4 CAMBREX CORP For: Apr 26 Filed by: Yanai Shlomo
www.streetinsider.com - May 1 at 9:03 AM |
 | Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex ...
globenewswire.com - April 27 at 9:27 AM |
| Cambrex to Announce First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 26 at 4:48 PM |
| Cambrex (CBM) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:16 AM |
| Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility
finance.yahoo.com - April 23 at 8:47 AM |
| Cambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance Practices
finance.yahoo.com - April 19 at 5:01 PM |
 | vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback
www.bizjournals.com - April 18 at 9:01 AM |
| Cambrex Co. (CBM) Expected to Post Quarterly Sales of $110.80 Million
www.americanbankingnews.com - April 18 at 3:04 AM |
| Cambrex Invests in New Continuous Flow Technology at its High Point, NC Facility
finance.yahoo.com - April 17 at 9:18 AM |
| Cambrex Co. (CBM) Expected to Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - April 16 at 1:12 PM |
| Cambrex, poised for another expansion, buys two properties for $10.2M
www.bizjournals.com - April 16 at 8:55 AM |
| Cambrex (CBM) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:43 PM |
| Cambrex (CBM) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 10 at 9:17 AM |
| Cambrex Co. (CBM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 8 at 1:30 AM |
| Cleantech Building Materials: Notice of AGM
finance.yahoo.com - April 3 at 4:54 PM |
| Cambrex (CBM) Rating Reiterated by Craig Hallum
www.americanbankingnews.com - April 2 at 8:04 PM |
| Cambrex Co. (CBM) Expected to Announce Quarterly Sales of $110.80 Million
www.americanbankingnews.com - April 1 at 2:54 AM |
| Zacks: Brokerages Anticipate Cambrex Co. (CBM) Will Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - March 30 at 3:10 PM |
| Cleantech Building Materials: Annual Results to 31 December 2017
finance.yahoo.com - March 29 at 9:16 AM |
| Cambrex (CBM) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM |
| Cleantech Building Materials: Application to Wiener Börse
finance.yahoo.com - March 16 at 9:11 AM |
| Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4%
finance.yahoo.com - March 16 at 9:11 AM |
| Should Value Investors Pick Cambrex (CBM) Stock?
finance.yahoo.com - March 15 at 5:25 PM |
| $110.80 Million in Sales Expected for Cambrex Co. (CBM) This Quarter
www.americanbankingnews.com - March 15 at 4:58 AM |
| Cambrex Co. (CBM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 14 at 1:54 AM |
| Zacks: Analysts Anticipate Cambrex Co. (CBM) to Post $0.31 Earnings Per Share
www.americanbankingnews.com - March 13 at 12:50 PM |
| Cambrex Co. (CBM) Holdings Trimmed by Ranger Investment Management L.P.
www.americanbankingnews.com - March 5 at 3:37 PM |
| Lazard Asset Management LLC Invests $22.20 Million in Cambrex Co. (CBM)
www.americanbankingnews.com - March 5 at 11:11 AM |
| Cambrex Co. (CBM) Shares Sold by Bank of New York Mellon Corp
www.americanbankingnews.com - March 5 at 5:00 AM |
| Cambrex Co. (CBM) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 3 at 3:30 PM |
| Royce & Associates LP Has $4.30 Million Holdings in Cambrex Co. (CBM)
www.americanbankingnews.com - March 3 at 9:12 AM |
| Cambrex Co. (CBM) Stake Lessened by King Luther Capital Management Corp
www.americanbankingnews.com - March 2 at 12:33 PM |
| AlphaOne Investment Services LLC Reduces Stake in Cambrex Co. (CBM)
www.americanbankingnews.com - February 26 at 5:14 AM |
| Cambrex Co. (CBM) Shares Bought by Pinebridge Investments L.P.
www.americanbankingnews.com - February 25 at 9:30 AM |
Cambrex (NYSE:CBM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement
Cambrex (NYSE CBM) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
